Generation Bio Co. (GBIO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
301 Binney Street
Cambridge, MA 02142
United States of America (the)
Phone
617 655 7500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
115
First IPO Date
June 12, 2020
| Name | Title | Pay | Year Born |
| Yalonda Howze | Interim CEO & President | 568,809 | 1972 |
| Kevin John Conway | Chief Financial Officer | 668,209 | N/A |
| Phillip Samayoa | Chief Scientific Officer | 680,956 | 1987 |
| Antoinette Paone | Chief Operating Officer | 681,155 | 1979 |
| Caitlin Cooper | Senior Vice President & Head of Business Development | 0 | N/A |
| Mark D. Angelino | Co-Founder | 0 | 1973 |
| Robert Kotin | Co-Founder | 0 | 1956 |
| Jasmin Tower | Chief Human Resources Officer | 0 | N/A |
Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.